Workflow
Bio-Rad(BIO)
icon
Search documents
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
Prnewswire· 2024-08-07 10:30
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. Full year organic revenue increased 1% (2% reported) to $1.2 billion. GAAP earnings per share (EPS) was $0.25 versus $0.47 one year ago. Delivered adjusted EPS of $0.49 compared to $0.55 one year ago. Full year GAAP EPS was $1.05 versus ...
Bio-Rad(BIO) - 2024 Q2 - Quarterly Report
2024-08-02 20:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIO.B New York Stock Exchange For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
ZACKS· 2024-08-02 15:22
Bio-Rad Laboratories, Inc. (BIO) posted second-quarter 2024 adjusted earnings per share (EPS) of $3.11, which beat the Zacks Consensus Estimate by 46.7%. The bottom line increased 3.7% from the prior-year quarter's levels. The quarter's adjustments primarily eliminate the impacts of certain non-recurring items like the amortization of purchased intangibles, restructuring costs and losses from the change in the fair market value of equity securities, among others. The company's GAAP loss was $76.26 per share ...
Bio-Rad(BIO) - 2024 Q2 - Earnings Call Transcript
2024-08-02 02:47
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President and CEO Andy Last - Executive Vice President and Chief Operating Officer Roop Lakkaraju - Executive Vice President and CFO Conference Call Participants Patrick Donnelly - Citi Daniel Leonard - UBS Tycho Peterson - Jefferies Jack Meehan - Nephron Research Operator Good day, everyone, and wel ...
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
ZACKS· 2024-08-01 22:26
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.11 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $3 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 46.70%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $2.04 per share when it actually produced earnings of $2.29, delivering a surprise of 12.25 ...
Bio-Rad(BIO) - 2024 Q2 - Quarterly Results
2024-08-01 20:18
Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2024 Financial Results HERCULES, Calif.—August 1, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percent compared to $681.1 million reported for the second quarter of 2023. On a currency-neutral basis, quarterly sa ...
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
ZACKS· 2024-07-31 17:01
With the second-quarter earnings season in full swing, it's going to be a pivotal week for numerous firms within the medical device sector. The latest Earnings Preview report indicates strong earnings and revenue growth within the Medical sector. The top and bottom-line improvements are likely to have been due to sustained demand for medical products and services and favorable pricing strategies, which might have offset the burden of increased costs and interest expenses stemming from worldwide geopolitical ...
BIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM
Prnewswire· 2024-07-31 11:00
Simple Western instruments are fully automated, capillary western systems designed to resolve proteins based on molecular weight followed by immunodetection. Simple Western Systems replace traditional western blotting workflows by offering improvements in data quality and speed. The enhanced quantitation, reproducibility and throughput Leo now provides makes it possible for scientists to adopt western-based readouts in applications where westerns are not typically used due to inadequate reproducibility and ...
All You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy
ZACKS· 2024-07-30 17:00
Investors might want to bet on Bio-Rad Laboratories (BIO) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. For Bio-Rad, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher. Harnessing the Power of ...
BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO
Prnewswire· 2024-07-29 11:00
MINNEAPOLIS, July 29, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. BioTechne joined Foresite Capital, and other investors, in this funding round. "We are excited to invest in Spear Bio," said Kim Kelderman, President and Chief Executive Officer of BioTechne. "Spear Bi ...